A Blood Based Mitochondrial Functional Index Biomarker for Alzheimer's Disease

Area of Science:

• Neuroscience
• Biomarker Discovery
• Mitochondrial Biology

Background:

• Alzheimer's disease (AD) pathology is linked to mitochondrial dysfunction.
• Emerging AD therapies target mitochondrial function, necessitating reliable biomarkers.
• Measuring mitochondrial function is crucial for AD research and treatment.

Purpose of the Study:

• To evaluate the utility of a novel blood-based mitochondrial biomarker, the mitochondrial functional index (MFI).
• To assess MFI's potential as a diagnostic and prognostic tool for Alzheimer's disease.

Main Methods:

• Developed and validated the mitochondrial functional index (MFI) as a blood-based biomarker.
• Assessed MFI in in vitro and in vivo AD models.
• Measured MFI in human subjects with AD and APOE4 carriers.
• Performed ROC analysis and correlated MFI with cognitive assessments (MMSE, CDR).

Main Results:

• MFI was significantly reduced in both AD models and human AD subjects.
• Lower MFI levels were observed in APOE4 carriers.
• MFI demonstrated superior diagnostic performance compared to other plasma biomarkers.
• MFI showed a positive correlation with cognitive function scores (MMSE and CDR).

Conclusions:

• The mitochondrial functional index (MFI) shows significant potential as a functional blood-based biomarker for assessing energy metabolism in Alzheimer's disease.
• MFI may serve as a valuable tool for AD diagnosis, prognosis, and monitoring therapeutic interventions.
• Further research is ongoing to explore the relationship between MFI and brain energy metabolism.